CLAIMS

1. An immunogenic composition comprising at least 2 different *S. pneumoniae* capsular saccharides, wherein one or more is/are selected from a first group consisting of serotypes 1, 3, 19A and 19F which is/are linked to a protein carrier(s) either directly or indirectly through a chemistry other than reductive amination, and one or more different saccharides is/are selected from a second group consisting of serotypes 4, 5, 6A, 6B, 7F, 9V, 14, 18C and 23F which is/are linked to a protein carrier(s) by reductive amination.
2. The immunogenic composition of claim 1 comprising a *S. pneumoniae* capsular saccharide from serotype 1 conjugated to a protein carrier through a chemistry other than reductive animation optionally wherein the saccharide from serotype 1 is conjugated to the protein carrier through a cyanylation chemistry, for example CDAP chemistry.
3. The immunogenic composition of any one of claims 1-2 comprising a *S. pneumoniae* capsular saccharide from serotype 19A conjugated to a protein carrier through a chemistry other than reductive animation optionally wherein the saccharide from serotype 19A is conjugated to the protein carrier through cyanylation chemistry, for example CDAP chemistry.
4. The immunogenic composition of any one of claims 1-3 comprising a *S. pneumoniae* capsular saccharide from serotype 19F conjugated to a protein carrier through a chemistry other than reductive animation optionally wherein the saccharide from serotype 19F is conjugated to the protein carrier through cyanylation chemistry, for example CDAP chemistry.
5. The immunogenic composition of any one of claims 1-4 comprising a *S. pneumoniae* capsular saccharide from serotype 4 conjugated to a protein carrier by reductive amination.
6. The immunogenic composition of any one of claims 1-5 comprising a *S. pneumoniae* capsular saccharide from serotype 5 conjugated to a protein carrier by reductive amination.
7. The immunogenic composition of any one of claims 1-6 comprising a *S. pneumoniae* capsular saccharide from serotype 6A conjugated to a protein carrier by reductive amination.
8. The immunogenic composition of any one of claims 1-7 comprising a *S. pneumoniae* capsular saccharide from serotype 6B conjugated to a protein carrier by reductive amination.
9. The immunogenic composition of any one of claims 1-8 comprising a *S. pneumoniae* capsular saccharide from serotype 7F conjugated to a protein carrier by reductive amination.
10. The immunogenic composition of any one of claims 1-9 comprising a *S. pneumoniae* capsular saccharide from serotype 9V conjugated to a protein carrier by reductive amination.

11. The immunogenic composition of any one of claims 1-10 comprising a *S. pneumoniae* capsular saccharide from serotype 14 conjugated to a protein carrier by reductive amination.
12. The immunogenic composition of any one of claims 1-11 comprising a *S. pneumoniae* capsular saccharide from serotype 18C conjugated to a protein carrier by reductive amination.
13. The immunogenic composition of any one of claims 1-12 comprising a *S. pneumoniae* capsular saccharide from serotype 23F conjugated to a protein carrier by reductive amination.
14. The immunogenic composition of any proceeding claim wherein the carrier protein is selected from the group consisting of tetanus toxoid, diphtheria toxoid, CRM197, Protein D, pneumolysin and PhtD or fragments or fusion proteins thereof.
15. The immunogenic composition of any preceding claim which further comprises one or more unconjugated or conjugated *S pneumoniae* proteins optionally wherein said one or more *S. pneumoniae* proteins are selected from Poly Histidine Triad family (PhtX), Choline Binding Protein family (CbpX), CbpX truncates, LytX family, LytX truncates, CbpX truncate-LytX truncate chimeric proteins, detoxified pneumolysin (Ply), PspA, PsaA, Sp128, Sp101, Sp130, Sp125 and Sp133 .
16. The immunogenic composition according to any preceding claim which further comprises an adjuvant.
17. The immunogenic composition of claims 1-16 for use in the treatment of prevention of disease caused by *Streptococcus pneumoniae* infection.

CLAIMS

1. An immunogenic composition comprising at least 2 different *S. pneumoniae* capsular saccharides, wherein one or more is/are selected from a first group consisting of serotypes 1, 3, 19A and 19F which is/are linked to a protein carrier(s) either directly or indirectly through a chemistry other than reductive amination, and one or more different saccharides is/are selected from a second group consisting of serotypes 4, 5, 6A, 6B, 7F, 9V, 14, 18C and 23F which is/are linked to a protein carrier(s) by reductive amination.

2. The immunogenic composition of claim 1 comprising a *S. pneumoniae* capsular saccharide from serotype 1 conjugated to a protein carrier through a chemistry other than reductive animation optionally wherein the saccharide from serotype 1 is conjugated to the protein carrier through a cyanylation chemistry, for example CDAP chemistry.

3. The immunogenic composition of any one of claims 1-2 comprising a *S. pneumoniae* capsular saccharide from serotype 19A conjugated to a protein carrier through a chemistry other than reductive animation optionally wherein the saccharide from serotype 19A is conjugated to the protein carrier through cyanylation chemistry, for example CDAP chemistry.

4. The immunogenic composition of any one of claims 1-3 comprising a *S. pneumoniae* capsular saccharide from serotype 19F conjugated to a protein carrier through a chemistry other than reductive animation optionally wherein the saccharide from serotype 19F is conjugated to the protein carrier through cyanylation chemistry, for example CDAP chemistry.

5. The immunogenic composition of any one of claims 1-4 comprising a *S. pneumoniae* capsular saccharide from serotype 4 conjugated to a protein carrier by reductive amination.

6. The immunogenic composition of any one of claims 1-5 comprising a *S. pneumoniae* capsular saccharide from serotype 5 conjugated to a protein carrier by reductive amination.

7. The immunogenic composition of any one of claims 1-6 comprising a *S. pneumoniae* capsular saccharide from serotype 6A conjugated to a protein carrier by reductive amination.

8. The immunogenic composition of any one of claims 1-7 comprising a *S. pneumoniae* capsular saccharide from serotype 6B conjugated to a protein carrier by reductive amination.

9. The immunogenic composition of any one of claims 1-8 comprising a *S. pneumoniae* capsular saccharide from serotype 7F conjugated to a protein carrier by reductive amination.

10. The immunogenic composition of any one of claims 1-9 comprising a *S. pneumoniae* capsular saccharide from serotype 9V conjugated to a protein carrier by reductive amination.

11. The immunogenic composition of any one of claims 1-10 comprising a *S. pneumoniae* capsular saccharide from serotype 14 conjugated to a protein carrier by reductive amination.

12. The immunogenic composition of any one of claims 1-11 comprising a *S. pneumoniae* capsular saccharide from serotype 18C conjugated to a protein carrier by reductive amination.

13. The immunogenic composition of any one of claims 1-12 comprising a *S. pneumoniae* capsular saccharide from serotype 23F conjugated to a protein carrier by reductive amination.

14. The immunogenic composition of any one of claim 1-13 wherein the carrier protein is selected from the group consisting of tetanus toxoid, diphtheria toxoid, CRM197, Protein D, pneumolysin and PhtD or fragments or fusion proteins thereof.

15. The immunogenic composition of any one of claims 1-14 which further comprises one or more unconjugated or conjugated *S pneumoniae* proteins optionally wherein said one or more *S. pneumoniae* proteins are selected from Poly Histidine Triad family (PhtX), Choline Binding Protein family (CbpX), CbpX truncates, LytX family, LytX truncates, CbpX truncate-LytX truncate chimeric

proteins, detoxified pneumolysin (Ply), PspA, PsaA, Sp128, Sp101, Sp130, Sp125 and Sp133.

16. The immunogenic composition according to any one of claims 1-15 which further comprises an adjuvant.

17. The immunogenic composition of claims 1-16 for use in the treatment of prevention of disease caused by *Streptococcus pneumoniae* infection.

18. The immunogenic composition according to claim 1, substantially as hereinbefore described with reference to any of the Examples and/or Figures.